Sanofi plans to invest EUR 400 million ($477 million) over five years to create a vaccine-production site in Singapore.

In partnership with the Singapore Economic Development Board, the new site will mainly supply the Asian region and complement existing manufacturing capacities in Europe and North America.

The project is currently entering its design phase with construction expected to begin in the third quarter of 2021. The five-year project will see the site fully operational in the first quarter of 2026 once all qualifications and validations of the first manufactured vaccine have been completed.

The plant will be designed around a central unit housing several fully digitalized modules to allow production of three to four vaccines simultaneously versus only one in current industrial sites and will be able to apply vaccine-manufacturing technology platforms based on different cell types.

Overall, Sanofi has 12 vaccine-manufacturing facilities globally.

Source: Sanofi